Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Language
Document Type
Year range
1.
Journal of Spectroscopy ; 2023 (no pagination), 2023.
Article in English | EMBASE | ID: covidwho-2271080

ABSTRACT

The wide range of symptoms of the coronavirus disease 2019 (COVID-19) makes it challenging to predict the disease evolution using a single parameter. Therefore, to describe the pathophysiological response to SARS-CoV-2 infection in hospitalized patients with severe COVID-19, we compared according to survival or death, the sociodemographic and clinical characteristics, the biochemical and immunological attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectra from saliva samples and their correlation with chemometric findings. Herein, we demonstrate that ATR-FTIR spectroscopy allows the description of the events related to cell damage, such as lipids biogenesis and the secondary structure of proteins associated with lactate dehydrogenase and albumin levels. Moreover, humoral (IgM) and cellular (IFN-gamma, TNF-alpha, IL-10, and IL-6) responses were also increased in patients who died from COVID-19. Copyright © 2023 Adriana Martinez-Cuazitl et al.

2.
Eur Rev Med Pharmacol Sci ; 25(19): 5942-5946, 2021 10.
Article in English | MEDLINE | ID: covidwho-1478936

ABSTRACT

OBJECTIVE: The pandemic disease by SARS-CoV-2 infection does not have an effective treatment. To prevent the disease, scientists developed vaccines that the clinicians use as an emergency licensed vaccine. The objective of this study was to determine the side effects in personnel vaccinated at the Military Central Hospital of Mexico with the BNT162b2 vaccine. PATIENTS AND METHODS: This study included the subjects who had received both doses of the BNT162b2 vaccine between December 2020 and February 2021. We asked about the side effects after the first and the second vaccine doses. One group had no history of COVID-19, and the second had a history of COVID-19. ANTI-SARS-CoV-2 antibodies were measured by the immunodetection technique in the second group only. RESULTS: We included 946 participants, 62% were women, and 80% were without comorbidities; 680 were included in the first group, and only 266 were in the second group. After the first dose, 77% of the first group and 86% of the second group presented some side effects. After the second dose, 84% of the first group and 89% of the second group showed some side effects. The main side effect was mild pain. All participants (126) were IgG positive, and only 26.9% were IgM positive at 17.5 days (12.8 days, 20.3 days) after the second dose. CONCLUSIONS: There is a positive correlation between side effects after the first dose in patients with a history of previous SARS-CoV-2 infection compared to those who did not. Nevertheless, this correlation is not present after the second dose. The low percentage of IgM could be related to the time interval between vaccination and sample measure.


Subject(s)
COVID-19 Vaccines/adverse effects , Hospitals, Military/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , BNT162 Vaccine , COVID-19/complications , COVID-19/diagnosis , COVID-19 Vaccines/administration & dosage , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Male , Mexico , Middle Aged , Military Personnel , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL